Next-Generation Stem Cells Cleared for Human Trial
By David Cyranoski,
Nature
| 09. 10. 2014
A Japanese patient with a debilitating eye disease is about to become the first person to be treated with induced pluripotent stem cells, which have generated enthusiastic expectations and earned their inventor a Nobel Prize. A health-ministry committee has vetted researchers' safety tests and cleared the team to begin the experimental procedure.
[Update 12 September: eye specialist Yasuo Kurimoto has now performed the procedure on the first patient, a 70-year-old woman. See 'Japanese woman is first recipient of next-generation stem cells'.]
Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology (CDB) in Kobe, has been using induced pluripotent stem (iPS) cells to prepare a treatment for age-related macular degeneration. Unlike embryonic stem cells, iPS cells are produced from adult cells, so they can be genetically tailored to each recipient. They are capable of becoming any cell type in the body, and have the potential to treat a wide range of diseases. The CDB trial will be the first opportunity for the technology to prove its clinical value.
In age-related macular degeneration, extra blood vessels form...
Related Articles
By Judd Boaz and Elise Kinsella, ABC News | 03.17.2026
By Gabriele Pichlhofer and Tino Plümecke, Guest Contributors
| 03.25.2026
A German translation of this interview will be published in May 2026 in the German GID MAGAZIN, which focuses on the market for reproductive technologies. For more information, visit: Gen-ethisches Netzwerk
Egg donation is currently prohibited in Germany and Switzerland, but both countries have been debating its legalization for years. In Switzerland, a legal framework is currently being developed, with a first draft expected by the end of the year. Yet the debate rarely draws on scientific evidence. Instead...
By Charles Pulliam-Moore, The Verge | 03.21.2026
Like many people, director Valerie Veatch was intrigued when OpenAI first released its Sora text-to-video generative AI model to the public in 2024. Though she didn’t fully understand the technology, she was curious about what it could do, and she...
By Ritsuko Kawai, Wired | 03.14.2026
On March 6, Japan’s Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells.These will...
